

University of Groningen

Pharmacokinetics and optimal exposure of antifungal drugs in critically ill patients

van der Elst, Kimberly Corina Maria

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2015

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

van der Elst, K. C. M. (2015). *Pharmacokinetics and optimal exposure of antifungal drugs in critically ill patients*. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Pharmacokinetics and optimal exposure of antifungal drugs in
critically ill patients

Kim van der Elst

ISBN: 978-90-367-7864-0

ISBN: 978-90-367-7863-3 (electronic version)

The work described in this thesis was performed at the department of Clinical Pharmacy and Pharmacology of the University Medical Center Groningen.

Cover image: *Aspergillus Fumigatus*

Cover design: Kim van der Elst & Frank Bakker

Printed by: Ipskamp Drukkers, Enschede



rijksuniversiteit
 groningen

Pharmacokinetics and optimal exposure of antifungal drugs in critically ill patients

Proefschrift

ter verkrijging van de graad van doctor aan de
 Rijksuniversiteit Groningen
 op gezag van de
 rector magnificus prof. dr. E. Sterken
 en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op
 vrijdag 5 juni 2015 om 12:45 uur

door

Kimberly Corina Maria van der Elst

geboren op 20 december 1982
 te 's-Gravenhage

Promotores

Prof. dr. J.G.W. Kosterink
Prof. dr. T.S. van der Werf
Prof. dr. D.R.A. Uges

Co-promotor

Dr. J.W.C. Alffenaar

Beoordelingscommissie

Prof. dr. E.S. de Bont
Prof. dr. R.A.A. Mathôt
Prof. dr. P.E. Verweij

Contents

1	Introduction	1
1.1	Invasive fungal infections	1
1.2	Antifungal treatment	4
1.3	Pharmacokinetics and pharmacodynamics	6
1.4	Critically ill patients	7
1.5	Therapeutic Drug Monitoring	8
1.6	Aim of the thesis	8
1.7	Outline of the thesis	8
	Bibliography	11
2	Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically ill children	17
2.1	Introduction	17
2.2	Methods	18
2.2.1	Study design and data collection	18
2.2.2	Correlations with fluconazole concentration	19
2.2.3	Time to culture conversion	20
2.2.4	Statistical analysis	20
2.3	Results	20
2.3.1	Correlations with fluconazole concentration	21
2.3.2	Time to culture conversion	22
2.4	Discussion	26
2.5	Conclusion	28
	Bibliography	29

3	Clinical validation of the analysis of fluconazole in oral fluid in hospital-ized children	33
3.1	Introduction	33
3.2	Materials and Methods	34
3.2.1	Study design	34
3.2.2	Oral fluid method validation	35
3.2.3	Statistical analysis	36
3.3	Results	37
3.3.1	Analytical method validation	37
3.3.2	Clinical validation	38
3.4	Discussion	39
3.5	Conclusion	42
	Bibliography	43
4	Subtherapeutic posaconazole exposure and the relation with treatment out-come in patients at risk of and with invasive fungal disease	47
4.1	Introduction	48
4.2	Materials and methods	48
4.2.1	Study design and data collection	48
4.2.2	Posaconazole exposure	49
4.2.3	Treatment outcome and treatment optimization strategies	50
4.2.4	Statistical analysis	50
4.3	Results	52
4.3.1	Posaconazole exposure	52
4.3.2	Treatment outcome and treatment optimization strategies	53
4.4	Discussion	55
4.5	Conclusion	58
	Bibliography	59
5	Dried blood spot analysis suitable for therapeutic drug monitoring of voricon-azole, fluconazole, and posaconazole	65
5.1	Introduction	65
5.2	Materials and methods	66
5.2.1	Patients and sampling	66
5.2.2	DBS method validation	67
5.2.3	Patient preference	68
5.2.4	Statistical analysis	68
5.3	Results	69
5.3.1	Patient demographics and dose characteristics	69

Contents

5.3.2	DBS method validation	69
5.3.3	Clinical validation	70
5.3.4	Patient preference	71
5.4	Discussion	72
5.5	Conclusion	74
	Bibliography	77
6	Simultaneous quantification of anidulafungin and caspofungin in plasma by an accurate and simple liquid chromatography tandem mass spectrometric method	81
6.1	Introduction	82
6.2	Materials and methods	82
6.2.1	Chemicals and reagents	82
6.2.2	Equipment	84
6.2.3	Calibrators and quality control samples	84
6.2.4	Sample processing	84
6.2.5	LC-MS/MS conditions	85
6.2.6	Calibration and calculation	85
6.2.7	Method validation	85
6.2.8	Application of the method	87
6.3	Results	88
6.3.1	Application of the method	91
6.4	Discussion	91
6.5	Conclusion	93
	Bibliography	94
7	Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction	97
7.1	Introduction	97
7.2	Case report	98
7.3	Discussion	100
7.4	Conclusion	101
	Bibliography	102
8	The exposure and optimal dose of caspofungin in critically ill patients	105
8.1	Introduction	105
8.2	Methods	106
8.2.1	Study design	106
8.2.2	Data collection	107
8.2.3	Statistical analysis	108

8.3	Results	108
8.3.1	Caspofungin pharmacokinetics and exposure	109
8.4	Discussion	111
8.5	Conclusion	113
	Bibliography	114
9	General discussion & future perspectives	119
9.1	Critically ill pediatric patients	119
9.2	Patients on the intensive care unit	120
9.3	Immunocompromised patients	121
9.4	Therapeutic Drug Monitoring	121
9.5	Therapeutic drug management	122
9.6	Final remarks	123
	Bibliography	124
	Summary	130
	Samenvatting	135
	Dankwoord	139
	Publications	143
	Curriculum Vitae	145